Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this�…

Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer management.
However, molecular determinants of response to ICIs remain incompletely understood�…

Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features�…

Over the past few years, the development of immune checkpoint inhibitors has altered the
treatment paradigm in non–small cell lung cancer (NSCLC). Enrichment strategies have�…

Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical
responses in subsets of cancer patients across multiple indications, including non-small cell�…

Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome�…

Despite progress in immunotherapy, identifying patients that respond has remained a
challenge. Through analysis of whole-exome and targeted sequence data from 5,449�…

Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…

Background Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with�…

Immune checkpoint inhibitors radically changed the treatment of patients with non-small cell
lung cancer (NSCLC). However, only one-quarter of patients benefit from these new�…